



Host Susceptibility Genes for Pulmonary NTM Disease Identified by International Network



Ho Namkoong

Organization Keio University School of Medicine, Department of Infectious Diseases

Current Position Professor

Educational background

2020 M.P.H., Johns Hopkins Bloomberg School of Public Health, Baltimore

2018 Ph.D., Keio University, Graduate School of Medicine, Tokyo

2007 M.D., Keio University School of Medicine, Tokyo

Professional experience

2025-Present Professor, Department of Infectious Diseases, Keio University School of Medicine Director, Division of Infectious Diseases and

Infection Control, Keio University Hospital

Director, Clinical Infectious Diseases Center, Keio University Hospital

2021-2024 Assistant Professor, Department of Infectious Diseases, Keio University School of Medicine

2018-2021 Postdoctoral Fellow, NIH/NIAID, Bethesda

2015-2018 Eiju General Hospital, Tokyo

Pulmonary nontuberculous mycobacterial (NTM) disease is a chronic, progressive pulmonary infection caused by low-virulence environmental pathogens. The global incidence of NTM disease has been steadily rising, posing an increasing public health concern. Despite this trend, current antimicrobial therapies remain suboptimal due to limited efficacy, the difficulty of developing new drugs, and the risk of antimicrobial resistance resulting from prolonged treatment. These challenges underscore the urgent need for novel therapeutic strategies grounded in a deeper understanding of disease pathogenesis.

Given the ubiquitous presence of NTM in the environment and its relatively low pathogenicity, previous epidemiological findings—including familial clustering and a higher incidence among Asians compared to other ethnic groups in the United States—suggest that host genetic factors play a critical role in susceptibility. However, until recently, genetic research on pulmonary NTM disease has been limited.

To address this gap, we conducted the first genome-wide association study (GWAS) of pulmonary Mycobacterium avium complex (MAC) disease, comprising 1,066 patients and 1,135 controls. This study identified a significant association at the CHP2 locus on chromosome 16p21. The lead single nucleotide polymorphism (SNP), rs109592, was associated with decreased CHP2 expression in lung tissue and was particularly linked to the nodular bronchiectasis subtype. Notably, the risk allele demonstrated consistent effects across both Japanese and European populations, suggesting a shared genetic architecture. Since CHP2 encodes a protein involved in intracellular pH and ion homeostasis, this discovery provides novel insight into the molecular basis of host susceptibility to pulmonary MAC disease.

Building upon these findings, we plan to expand our international collaborative network and conduct transethnic meta-GWAS analyses, including additional cohorts from Korea and other Asia-Pacific regions.